Kasumi-1 (ATCC® CRL-2724)

Organism: Homo sapiens, human  /  Cell Type: myeloblast  /  Tissue: peripheral blood  /  Disease: acute myeloblastic leukemia

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue peripheral blood
Cell Type myeloblast
Product Format frozen
Morphology myeloblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease acute myeloblastic leukemia
Age 7 years
Gender male
Ethnicity Japanese
Storage Conditions liquid nitrogen vapor phase
Karyotype t(8:21) (q22;q22)
Images
Derivation
The cell line was established from the peripheral blood of an acute myeloid leukemia (AML) patient.
Clinical Data
7 yrs juvenile
Japanese
male
­
Comments

This is a leukemic cell line with an 8;21 chromosome translocation. This translocation juxtaposes the AML1 with ETO (or MTG8) gene, giving rise to the fusion gene AML1-ETO (also known as AML1-MTG or RUNX1-CBF2T1), hence the cells produce chimeric AML1-ETO protein. This protein down-regulates CEBPA mRNA, protein and DNA binding activity, which is crucial for the differentiation of granulocytes.

The cells are positive for myeloperoxidase showing a morphology of myeloid maturation.

In proliferation assay the cells in culture showed response to interleukin-3 (IL-3), IL-6, granulocyte colony-stimulating factor (G-CSF), and granulocytemacrophage CSF (GM-CSF), but not to IL-1 or IL-5.

Neither granulocytic nor eosinophilic maturation was observed in the in vitro liquid culture by the addition of dimethyl sulfoxide, G-CSF, or IL-5, respectively. Induction of macrophagelike cells was seen by the addition of phorbol ester. Proliferation is inhibited by 1,25S-(OH)2-16,23-diene-26-F3-10-nor D3.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
Subculturing
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 3 x 105 viable cells/mL.

Interval: Maintain cell density between 3 x 105 and 3 x 106 viable cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)

Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
STR Profile
D5S818: 9,11
D13S317: 11,13
D7S820: 8,11
D16S539: 9,12
vWA: 14
THO1: 6,9
Amelogenin: X
TPOX: 8,9
CSF1PO: 10,12
Name of Depositor H Asou
Year of Origin November 8, 1989
References

Tashiro S, et al. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 77: 2031-2036, 1991. PubMed: 2018839

Miyoshi H, et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 12: 2715-2721, 1993. PubMed: 8334990

Miyoshi H, et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl. Acad. Sci. USA 88: 10431-10434, 1991. PubMed: 1720541

Asou H, et al. 19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood 92: 2441-2449, 1998. PubMed: 9746784

Kozu T, et al. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 82: 1270-1276, 1993. PubMed: 8353289

Pabst T, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat. Med. 7: 444-451, 2001. PubMed: 11283671

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

Tashiro S, et al. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 77: 2031-2036, 1991. PubMed: 2018839

Miyoshi H, et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 12: 2715-2721, 1993. PubMed: 8334990

Miyoshi H, et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl. Acad. Sci. USA 88: 10431-10434, 1991. PubMed: 1720541

Asou H, et al. 19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood 92: 2441-2449, 1998. PubMed: 9746784

Kozu T, et al. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 82: 1270-1276, 1993. PubMed: 8353289

Pabst T, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat. Med. 7: 444-451, 2001. PubMed: 11283671